J&J aims to have results of Covid-19 vaccine’s efficacy by end-2020 to mid-2021
Once a vaccine has been developed, J & may consider injecting healthy volunteers with Covid-19 if there are not enough patients for final trials, a company executive says
11 August 2020 - 17:33
Brussels — Johnson & Johnson (J & ) could produce one-billion doses of its potential Covid-19 vaccine in 2021 if it proves successful and would consider injecting healthy volunteers with the novel coronavirus if there were not enough patients for final trials, a company executive said.
J & began early-stage human safety trials for its potential Covid-19 vaccine in July after releasing details of a study in monkeys that showed its best-performing candidate offered strong protection in a single dose...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.